New drug combo shows promise for tough breast cancer

NCT ID NCT05852691

Ongoing Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 22 times

Summary

This study tests a new immunotherapy drug called tobemstomig combined with chemotherapy (nab-paclitaxel) for people with advanced triple-negative breast cancer that has not been treated before. The goal is to see if this combination works better than the current standard treatment (pembrolizumab plus chemo) at slowing cancer growth. About 83 participants will be enrolled, and the study is currently active but not recruiting.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

?wi?tokrzyskie Centrum Onkologii

Kielce, 25-734, Poland
Asan Medical Center

Seoul, 05505, South Korea
Avera Cancer Institute

Sioux Falls, South Dakota, 57105, United States
Cancer Blood and Specialty Clinic

Los Alamitos, California, 90720, United States
Centro Medico Monte Carmelo

Arequipa, 04001, Peru
Centro Médico Zambrano Hellion

Monterrey, Nuevo León, 66278, Mexico
Centro de Investigacion Clinica de Oaxaca

Oaxaca City, Oaxaca, 68020, Mexico
Centro de Investigaciones Médicas y Desarrollo LC S.R.L

Buenos Aires, C1113AAE, Argentina
Clinica de Pesquisa e Centro de Estudos em Oncologia Ginecologica e Mamaria Ltda

São Paulo, São Paulo, 01317-001, Brazil
Dres. Andreas Köhler und Roswitha Fuchs

Langen, 63225, Germany
Fakultni Thomayerova nemocnice

Praha 4 - Krc, 140 59, Czechia
Gangnam Severance Hospital, Yonsei University Health System

Seoul, 06273, South Korea
Hadassah University Hospital - Ein Kerem

Jerusaelm, 9112001, Israel
Health Pharma Professional Research

Mexico City, Mexico CITY (federal District), 03100, Mexico
Hospital Araujo Jorge

Goiânia, Goiás, 74605-070, Brazil
Hospital Quiron de Madrid

Pozuelo de Alarcón, Madrid, 28223, Spain
Hospital Universitario Virgen de La Arrixaca

El Palmar, Murcia, 30120, Spain
Hospital de Cancer de Barretos

Barretos, São Paulo, 14784-400, Brazil
Hospital do Cancer de Pernambuco - HCP

Recife, Pernambuco, 50040-000, Brazil
Instituto Nacional de Enfermedades Neoplasicas

Lima, Lima 34, Peru
Instituto Peruano de Oncología y Radioterapia

Lima, Peru
Klinikum Essen-Mitte Ev. Huyssens-Stiftung / Knappschafts GmbH

Essen, 45136, Germany
Komarom-Eszergom Varmegyei Szent Borbala Korhaz

Tatabánya, 2800, Hungary
Medical Oncology Centre of Rosebank

Johannesburg, 2196, South Africa
Memorial Sloan-Kettering Cancer Center

New York, New York, 10065, United States
National Taiwan Uni Hospital

Taipei, 100, Taiwan
Novant Health Presbyterain Medical Center

Charlotte, North Carolina, 28204, United States
OncoMed

Mexico City, Mexico CITY (federal District), 03100, Mexico
Oncosalud Sac

Lima, 41, Peru
Ospedale Provinciale Santa Maria Delle Croci

Ravenna, Emilia-Romagna, 48100, Italy
Ospedale San Raffaele

Milan, Lombardy, 20132, Italy
Samsung Medical Center

Seoul, 06351, South Korea
Seoul National University Hospital

Seoul, 03080, South Korea
Sheba Medical Center

Ramat Gan, 5262100, Israel
Sunshine Hospital

St Albans, Victoria, Australia
Szpital Uniwersytecki w Krakowie, Oddzia? Kliniczny Kliniki Onkologii

Krakow, 31-501, Poland
Universitätsklinikum Ulm Am Michelsberg

Ulm, 89075, Germany

Conditions

Explore the condition pages connected to this study.

BREAST CANCER